Table 3.
FGID according to demographic and clinical characteristics of the population.
| Total | FGID+ (75) | FGID- (45) | p value | |
|---|---|---|---|---|
| 120 | N (%) | N (%) | ||
| Sex | ||||
| Male | 58 | 33 (56.9) | 25 (43.1) | n.s. |
| Female | 62 | 42 (67.7) | 20 (32.3) | |
| Age of onset | ||||
| >10 years | 83 | 54 (65.1) | 29 (34.9) | n.s. |
| <10 years | 37 | 21 (56.8) | 16 (43.2) | |
| Disease duration | ||||
| <10 years | 25 | 18 (72.0) | 7 (28.0) | n.s. |
| >10 years | 95 | 57 (60.0) | 38 (40.0) | |
| Epilepsy syndrome | ||||
| Focal | 85 | 53 (62.4) | 32 (37.6) | n.s. |
| Epileptic encephalopathy | 3 | 2 (66.7) | 1 (33.3) | |
| Idiopathic generalized | 32 | 20 (62.5) | 12 (37.5) | |
| Etiology of focal epilepsies | ||||
| Symptomatic | 42 | 24 (57.1) | 18 (42.9) | n.s. |
| Unknown/idiopathic | 43 | 26 (60.5) | 17 (39.5) | |
| Response to therapy | ||||
| Responsive | 49 | 29 (61.2) | 20 (38.8) | n.s. |
| Drug-resistant | 71 | 46 (63.4) | 25 (36.6) | |
| Therapy regimen | ||||
| Polytherapy | 81 | 53 (65.4) | 28 (34.6) | n.s. |
| Monotherapy | 37 | 20 (54.1) | 17 (45.9) | |
| None | 2 | 2 (100) | 0 (0.0) | |
| ASM generation | ||||
| First generation | 85 | 48 (56.5) | 37 (43.5) | n.s. |
| Second/third generation | 33 | 25 (75.8) | 8 (24.2) | |
| Seizure rate in drug-resistant epilepsy | ||||
| Annual/monthly | 34 | 23 (67.6) | 11 (32.4) | n.s. |
| Weekly/daily | 37 | 23 (62.2) | 14 (37.8) | |
| Lobar involvement in focal epilepsy | ||||
| Temporal | 39 | 30 (76.9) | 9 (23.1) | 0.02 |
| Extra-temporal | 46 | 23 (50.0) | 23 (50.0) | |
ASM, antiseizure medication; FGID, functional gastrointestinal disorder.